Purpose: The aim of this secondary analysis was to identify prodynorphin (PDYN) genetic markers moderating the therapeutic response to treatment of cocaine dependence with buprenorphine/naloxone (Suboxone®; BUP).
Methods: Cocaine-dependent participants (N = 302) were randomly assigned to a platform of injectable, extended-release naltrexone (XR-NTX) and one of three daily medication arms: 4 mg BUP (BUP4), 16 mg BUP (BUP16), or placebo (PLB) for 8 weeks (Parent Trial Registration: Protocol ID: NIDA-CTN-0048, Clinical Trials.gov ID: NCT01402492). DNA was obtained from 277 participants. Treatment response was determined from weeks 3 to 7 over each 1-week period by the number of cocaine-positive urines per total possible urines.
Results: In the cross-ancestry group, the PLB group had more cocaine-positive urines than the BUP16 group (P = 0.0021). The interactions of genetic variant × treatment were observed in the rs1022563 A-allele carrier group where the BUP16 group (N = 35) had fewer cocaine-positive urines (P = 0.0006) than did the PLB group (N = 26) and in the rs1997794 A-allele carrier group where the BUP16 group (N = 49) had fewer cocaine-positive urines (P = 0.0003) than did the PLB group (N = 58). No difference was observed in the rs1022563 GG or rs1997794 GG genotype groups between the BUP16 and PLB groups. In the African American-ancestry subgroup, only the rs1022563 A-allele carrier group was associated with treatment response.
Conclusion: These results suggest that PDYN variants may identify patients who are best suited to treatment with XR-NTX plus buprenorphine for cocaine use disorder pharmacotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00228-022-03302-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Differences in total and differential white blood cell counts and in inflammatory parameters between psychiatric inpatients with and without recent consumption of cannabinoids, opioids, or cocaine: A retrospective single-center study.
Brain Behav Immun Health
December 2024
Biomedical Network Research Centre on Mental Health (CIBERSAM), Madrid, Spain.
Article Synopsis
- * A study analyzed immune parameters in 927 psychiatric inpatients, revealing that those who tested positive for these substances had notably higher white blood cell (WBC) counts and other immune markers than those with negative tests.
- * The results indicated that cannabinoid users experienced a significant increase in neutrophils, while cocaine users showed heightened eosinophil counts, suggesting that different substances may uniquely influence immune responses in individuals with psychiatric disorders.
Assessing risk of major adverse cardiac events among patients with chest pain and cocaine use using the HEART score.
Am J Emerg Med
June 2024
Department of Emergency Medicine, University of Maryland School of Medicine, Baltimore, MD, USA; Research Associate Program, Department of Emergency Medicine, University of Maryland School of Medicine, Baltimore, MD, USA; Program in Trauma, R Adam Cowley Shock Trauma Center, University of Maryland School of Medicine, Baltimore, MD, USA.
Introduction: Chest pain (CP), a common presentation in the emergency department (ED) setting, is associated with significant morbidity and mortality if emergency clinicians miss the diagnosis of acute coronary syndrome (ACS). The HEART (History, Electrocardiogram, Age, Risk Factors, Troponin) score had been validated for risk-stratification patients who are at high risk for ACS and major adverse cardiac events (MACE). However, the use of cocaine as a risk factor of the HEART score was controversial.
View Article and Find Full Text PDFIndividual-Level Risk Prediction of Return to Use During Opioid Use Disorder Treatment.
JAMA Psychiatry
January 2024
Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York.
Importance: No existing model allows clinicians to predict whether patients might return to opioid use in the early stages of treatment for opioid use disorder.
Objective: To develop an individual-level prediction tool for risk of return to use in opioid use disorder.
Design, Setting, And Participants: This decision analytical model used predictive modeling with individual-level data harmonized in June 1, 2019, to October 1, 2022, from 3 multicenter, pragmatic, randomized clinical trials of at least 12 weeks' duration within the National Institute on Drug Abuse Clinical Trials Network (CTN) performed between 2006 and 2016.
Trends in Drug Tests among Children: A 22-Year Retrospective Analysis.
Pathophysiology
May 2023
Department of Computer Science, LSU Shreveport, Shreveport, LA 71115, USA.
There are several pathophysiological outcomes associated with substance abuse including metabolic disbalance, neurodegeneration, and disordered redox. Drug use in pregnant women is a topic of great concern due to developmental harm which may occur during gestation and the associated complications in the neonate after delivery. We sought to determine what the trajectory of drug use is like in children aged 0-4 years and mothers of neonates.
View Article and Find Full Text PDFImpulsivity and Treatment Outcomes in Individuals with Cocaine Use Disorder: Examining the Gap between Interest and Adherence.
Subst Use Misuse
May 2023
Division on Substance Use Disorders, New York State Psychiatric Institute and Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons and Columbia, University Irving Medical Center, New York, NY, USA.
: Impulsivity is implicated in the development and maintenance of Cocaine Use Disorder (CUD). Less work has examined impulsivity's role on interest in initiating treatment, treatment adherence, or treatment response. No pharmacotherapies are approved for CUD, so efforts to understand and bolster the effects of psychotherapy are important in guiding and refining treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!